Clinical relevance of mutations in the Wilms tumor suppressor 1 gene <i>WT1</i> and the cadherin‐associated protein β1 gene <i>CTNNB1</i> for patients with Wilms tumors

Abstract

Patients with WT1 germline mutations had an increased risk for bilateral disease and second tumor events. Therefore, the authors concluded that tumor surveillance until adulthood should be considered. Although tumors with both WT1 and CTNNB1 mutations had a poor volumetric response, there was no significant difference in overall survival in this cohort of patients with and without WT1 mutations.